SiRNA delivery: Challenges and role of carrier systems

Pharmazie

Volumn 66, Issue 5, 2011, Pages 313-318

  Shegokar, Ranjita ^a   Shaal, L A L ^a   Mishra, P R ^b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; POLYMER; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE;

CHEMICAL MODIFICATION; GENE DELIVERY SYSTEM; HETEROZYGOTE; NANODEVICE; NANOEMULSION; NONHUMAN; REVIEW; RNA INTERFERENCE;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EMULSIONS; GENE TARGETING; GENE THERAPY; HUMANS; LIPIDS; LIPOSOMES; NANOPARTICLES; POLYMERS; RNA, SMALL INTERFERING;

EID: 79957631803     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2011.0301     Document Type: Review

References (90)

1. Akhtar S, Benter I (2007a) Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev 59: 164-182. (Pubitemid 46773052)
2. Akhtar S, Benter I (2007b) Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev 59: 164-182. (Pubitemid 46773052)
3. Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N, Bacallado SA, Nguyen DN, Fuller J, Alvarez R, Borodovsky A, Borland T, Constien R, de Fougerolles A, Dorkin JR, Narayanannair Jayaprakash K, Jayaraman M, John M, Koteliansky V, Manoharan M, Nechev L, Qin J, Racie T, Raitcheva D, Rajeev KG, Sah DW, Soutschek J, Toudjarska I, Vornlocher HP, Zimmermann TS, Langer R, Anderson DG (2008) A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 26: 561-569. (Pubitemid 351668042)
4. Asokan A, Cho MJ (2002) Exploitation of intracellular pH gradients in the cellular delivery of macromolecules. J Pharm Sci 91: 903-913. (Pubitemid 34640914)
5. Austin CD, Wen X, Gazzard L, Nelson C, Scheller RH, Scales SJ (2005) Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates. Proc Natl Acad Sci USA 102: 17987-17992. (Pubitemid 41798489)
6. Baker M (2010) RNA interference: Homing in on delivery. Nature 464 (7292): 1225-1228.
7. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME (2007) Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 104: 15549-15554. (Pubitemid 47502954)
8. Belyantseva IA (2009) Helios Gene Gun-mediated transfection of the inner ear sensory epithelium. Methods Mol Biol 493: 103-123.
9. Bernstein E, Caudy AA, Hammond SM, Hannon GJ (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409: 363-366. (Pubitemid 32151243)
10. Bhattacharya S, Bajaj A (2009) Advances in gene delivery through molecular design of cationic lipids. Chem Commun (Camb) 31: 4632-4656.
11. Boado RJ (2007) Blood-brain barrier transport of non-viral gene and RNAi therapeutics. Pharm Res 24: 1772-1787.
12. Boeckle S, von Gersdorff K, van der Piepen S, Culmsee C, Wagner E, Ogris M (2004) Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer. J Gene Med 6: 1102-1111. (Pubitemid 40228122)
13. Braasch DA, Jensen S, Liu Y, Kaur K, Arar K, White MA, Corey DR (2003) RNA interference in mammalian cells by chemically-modified RNA. Biochemistry (Mosc) 42: 7967-7975. (Pubitemid 36807714)
14. Brown WL, Mastico RA, Wu M, Heal KG, Adams CJ, Murray JB, Simpson JC, Lord JM, Taylor-Robinson AW, Stockley PG (2002) RNA bacteriophage capsid-mediated drug delivery and epitope presentation. Intervirology 45: 371-380. (Pubitemid 36173447)
15. Chono S, Li SD, Conwell CC, Huang L (2008) An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Rel 131: 64-69.
16. Constantinides PP, Welzel G, Ellens H, Smith PL, Sturgis S, Yiv SH, Owen AJ (1996) Water-in-oil nanoemulsions containing medium-chain fatty acids/salts: formulation and intestinal absorption enhancement evaluation. Pharmacol Res 13: 210-215. (Pubitemid 26072140)
17. Cullis PR (2002) Stabilized plasmid-lipid particles for systemic gene therapy. Cell Molec Biol Lett 7: 226.
18. Davis ME, Pun SH, Bellocq NC, Reineke TM, Popielarski SR, Mishra S, Heidel JD (2004) Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers. Curr Med Chem 11: 179-197. (Pubitemid 38128844)
19. de Martimprey H, Bertrand JR, Fusco A, Santoro M, Couvreur P, Vauthier C, Malvy C (2008) siRNA nano formulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. Nucleic Acids Res 36: e2.
20. Doi N, Zenno S, Ueda R, Ohki-Hamazaki H, Ui-Tei K, Saigo K (2003) Short-interfering-RNA-mediated gene silencing in mammalian cells requires Dicer and eIF2C translation initiation factors. Curr Biol 13: 41-46. (Pubitemid 36080621)
21. Dorsett Y, Tuschl T (2004) siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Disc 3: 318-329. (Pubitemid 38499759)
22. Dykxhoorn DM, Novina CD, Sharp PA (2003) Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 4: 457-467. (Pubitemid 36648591)
23. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498. (Pubitemid 32494397)
24. Fenske DB, MacLachlan I, Cullis PR (2002) Stabilized plasmid-lipid particles: a systemic gene therapy vector. Methods Enzymol 346: 36-71. (Pubitemid 41103130)
25. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811. (Pubitemid 28099681)
26. Gary DJ, Puri N, Won YY (2007) Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Rel 121: 64-73. (Pubitemid 47126065)
27. Grayson AC, Doody AM, Putnam D (2006) Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm Res 23: 1868-1876. (Pubitemid 44200551)
28. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R (1994) Biodegradable long-circulating polymeric nanospheres. Science 263: 1600-1603. (Pubitemid 24128361)
29. Guo X, Szoka FC, Jr. (2003) Chemical approaches to triggerable lipid vesicles for drug and gene delivery. Acc Chem Res 36: 335-341.
30. Hanai K, Takeshita F, Honma K, Nagahara S, Maeda M, Minakuchi Y, Sano A, Ochiya T (2006) Atelocollagen-mediated systemic DDS for nucleic acid medicines. Ann NY Acad Sci 1082: 9-17. (Pubitemid 44955443)
31. Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK, Kornbrust DJ, Davis ME (2007) Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA 104: 5715-5721. (Pubitemid 47175600)
32. Heyes J, Palmer L, Bremner K, MacLachlan I (2005) Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Rel 107: 276-287. (Pubitemid 41316290)
33. Howard KA, Rahbek UL, Liu X, Damgaard CK, Glud SZ, Andersen MO, Hovgaard MB, Schmitz A, Nyengaard JR, Besenbacher F, Kjems J (2006) RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther 14: 476-484.
34. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ (2005) Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 65: 8984-8992. (Pubitemid 41377390)
35. Hunter AC (2006) Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. Adv Drug Deliv Rev 58: 1523-1531.
36. Ilies MA, Seitz WA, Balaban AT (2002) Cationic lipids in gene delivery: principles, vector design and therapeutical applications. Curr Pharm Des 8: 2441-2473. (Pubitemid 35339324)
37. Juliano R, Alam MR, Dixit V, Kang H (2008) Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 36: 4158-4171. (Pubitemid 351984831)
38. Kabanov AV (1999) Taking polycation gene delivery systems from in vitro to in vivo. Pharm Sci Technol Today 2: 365-372.
39. Kaneda MM, Sasaki Y, Lanza GM, Milbrandt J, Wickline SA (2010) Mechanisms of nucleotide trafficking during siRNA delivery to endothelial cells using perfluorocarbon nanoemulsions. Biomaterials 31: 3079-3086.
40. Khalil IA, Kogure K, Futaki S, Hama S, Akita H, Ueno M, Kishida H, Kudoh M, Mishina Y, Kataoka K, Yamada M, Harashima H (2007) Octaarginine-modified multifunctional envelope-type nanoparticles for gene delivery. Gene Ther 14: 682-689. (Pubitemid 46585628)
41. Kim B, Tang Q, Biswas PS, Xu J, Schiffelers RM, Xie FY, Ansari AM, Scaria PV, Woodle MC, Lu P, Rouse BT (2004) Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am J Pathol 165: 2177-2185. (Pubitemid 39578394)
42. Kim HR, Kim IK, Bae KH, Lee SH, Lee Y, Park TG (2008) Cationic solid lipid nanoparticles reconstituted from lowdensity lipoprotein components for delivery of siRNA. Mol Pharmacol 5: 622-631.
43. Kumar P, Ban HS, Kim SS, Wu H, Pearson T, Greiner DL, Laouar A, Yao J, Haridas V, Habiro K, Yang YG, Jeong JH, Lee KY, Kim YH, Kim SW, Peipp M, Fey GH, Manjunath N, Shultz LD, Lee SK, Shankar P (2008) T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134: 577-586.
44. Landen CN, Jr., Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK (2005) Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65: 6910-6918.
45. Layzer JM, McCaffrey AP, Tanner AK, Huang Z, Kay MA, Sullenger BA (2004) In vivo activity of nuclease-resistant siRNAs. RNA 10: 766-771.
46. Leng Q, Goldgeier L, Zhu J, Cambell P, Ambulos N, Mixson AJ (2007) Histidine-lysine peptides as carriers of nucleic acids. Drug News Perspect 20: 77-86. (Pubitemid 46917230)
47. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20. (Pubitemid 40094598)
48. Li CX, Parker A, Menocal E, Xiang S, Borodyansky L, Fruehauf JH (2006) Delivery of RNA Interference. Cell Cycle 5: 2103-2109. (Pubitemid 44553744)
49. Li J, Chen YC, Tseng YC, Mozumdar S, Huang L (2009) Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Rel 142: 416-421.
50. Liu F, Huang L (2002a) Electric gene transfer to the liver following systemic administration of plasmid DNA. Gene Ther 9: 1116-1119.
51. Liu F, Huang L (2002b) A syringe electrode device for simultaneous injection of DNA and electrotransfer. Mol Ther 5: 323-328. (Pubitemid 34211228)
52. Liu F, Song Y, Liu D (1999) Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 6: 1258-1266. (Pubitemid 29359019)
53. Lu PY, Xie FY, Woodle MC (2003) siRNA-mediated antitumorgenesis for drug target validation and therapeutics. Curr Opin Mol Ther 5: 225-234. (Pubitemid 37185340)
54. Lv H, Zhang S, Wang B, Cui S, Yan J (2006) Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Rel 114: 100-109. (Pubitemid 44128621)
55. MacLachlan I, Cullis P, Graham RW (1999) Progress towards a synthetic virus for systemic gene therapy. Curr Opin Mol Ther 1: 252-259. (Pubitemid 29238429)
56. Martin B, Sainlos M, Aissaoui A, Oudrhiri N, Hauchecorne M, Vigneron JP, Lehn JM, Lehn P (2005) The design of cationic lipids for gene delivery. Curr Pharm Des 11: 375-394. (Pubitemid 40277864)
57. McNamara JO, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, Sullenger BA, Giangrande PH (2006) Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24: 1005-1015. (Pubitemid 44215395)
58. Miller AD (2008) Towards safe nanoparticle technologies for nucleic acid therapeutics. Tumori 94: 234-245.
59. Miyawaki-Shimizu K, Predescu D, Shimizu J, Broman M, Predescu S, Malik AB (2006) siRNA-induced caveolin-1 knockdown in mice increases lung vascular permeability via the junctional pathway. AJP Lung Cellular and Molecular Physicology 290: L405-413.
60. Müller RH, Shegokar R, Keck CM (2011) 20 Years of Lipid Nanoparticles (SLN and NLC): Present State Development and Industrial Applications. Curr Drug Discov Technol [Epub ahead of print] PMID: 21291409
61. Nakamura Y, Kogure K, Futaki S, Harashima H (2007) Octaarginine-modified multifunctional envelope-type nano device for siRNA. J Control Release 119: 360-367. (Pubitemid 46770881)
62. Needham D, Anyarambhatla G, Kong G, Dewhirst MW (2000) A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 60: 1197-1201. (Pubitemid 30151982)
63. Nguyen DN, Chen SC, Lu J, Goldberg M, Kim P, Sprague A, Novobrantseva T, Sherman J, Shulga-Morskaya S, de Fougerolles A, Chen J, Langer R, Anderson DG (2009) Drug delivery-mediated control of RNA immunostimulation. Mol Ther 17: 1555-1562.
64. Ogris M, Wagner E (2002) Targeting tumors with non-viral gene delivery systems. Drug Discovery Today 7: 479-485. (Pubitemid 34532575)
65. Palliser D, Chowdhury D, Wang QY, Lee SJ, Bronson RT, Knipe DM, Lieberman J (2006) An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439: 89-94. (Pubitemid 43053634)
66. Pille JY, Li H, Blot E, Bertrand JR, Pritchard LL, Opolon P, Maksimenko A, Lu H, Vannier JP, Soria J, Malvy C, Soria C (2006) Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum Gene Ther 17: 1019-1026. (Pubitemid 46076743)
67. Popielarski SR, Hu-Lieskovan S, French SW, Triche TJ, Davis ME (2005)A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 2. In vitro and in vivo uptake results. Bioconjug Chem 16: 1071-1080. (Pubitemid 41368107)
68. Rao NM (2010) Cationic lipid-mediated nucleic acid delivery: beyond being cationic. Chem Phys Lipids 163: 245-252.
69. Santel A, Aleku M, Keil O, Endruschat J, Esche V, Fisch G, Dames S, Loffler K, Fechtner M, Arnold W, Giese K, Klippel A, Kaufmann J (2006) A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 13: 1222-1234. (Pubitemid 44184716)
70. Sato A, Takagi M, Shimamoto A, Kawakami S, Hashida M (2007) Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials 28: 1434-1442. (Pubitemid 44959042)
71. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria PV, Woodle MC (2004) Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32: e149.
72. Schiffelers RM, Storm G (2006) ICS-283: a system for targeted intravenous delivery of siRNA. Expert Opinion on Drug Delivery 3: 445-454. (Pubitemid 43772718)
73. Shegokar R, Singh KK, Müller RH (2010) Int J Pharm Production & stability of stavudine solid lipid nanoparticles-From lab to industrial scale. [Epub ahead of print] PMID: 20727389
74. Sioud M (2010) RNA therapeutics: function, design, and delivery. Preface. Methods Mol Biol 629: v-vii.
75. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR (2003) Activation of the interferon system by short-interfering RNAs. Nature Cell Biol 5: 834-839. (Pubitemid 37087172)
76. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, Feng Y, Palliser D, Weiner DB, Shankar P, Marasco WA, Lieberman J (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23: 709-717.
77. Sorensen DR, Leirdal M, Sioud M (2003) Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 327: 761-766. (Pubitemid 36315917)
78. Suda T, Suda K, Liu D (2008) Computer-assisted hydrodynamic gene delivery. Mol Ther 16: 1098-1104. (Pubitemid 351737075)
79. Takeshita F, Minakuchi Y, Nagahara S, Honma K, Sasaki H, Hirai K, Teratani T, Namatame N, Yamamoto Y, Hanai K, Kato T, Sano A, Ochiya T (2005) Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 102: 12177-12182. (Pubitemid 41291148)
80. Tam P, Monck M, Lee D, Ludkovski O, Leng EC, Clow K, Stark H, Scherrer P, Graham RW, Cullis PR (2000) Stabilized plasmid-lipid particles for systemic gene therapy. Gene Ther 7: 1867-1874.
81. Tao W, Davide JP, Cai M, Zhang GJ, South VJ, Matter A, Ng B, Zhang Y, Sepp-Lorenzino L (2010) Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver. Mol Ther 18: 1657-1666.
82. Unger EC, Hersh E, Vannan M, Matsunaga TO, McCreery T (2001a) Local drug and gene delivery through microbubbles. Prog Cardiovasc Dis 44: 45-54. (Pubitemid 32807854)
83. Unger EC, Hersh E, Vannan M, McCreery T (2001b) Gene delivery using ultrasound contrast agents. Echocardiography 18: 355-361. (Pubitemid 32579099)
84. Watts JK, Deleavey GF, Damha MJ (2008) Chemically modified siRNA: tools and applications. Drug Discov Today 13: 842-855.
85. Wheeler JJ, Palmer L, Ossanlou M, MacLachlan I, Graham RW, Zhang YP, Hope MJ, Scherrer P, Cullis PR (1999) Stabilized plasmid-lipid particles: construction and characterization. Gene Ther 6: 271-281. (Pubitemid 29089926)
86. Wu H, Ramachandran C, Bielinska AU, Kingzett K, Sun R, Weiner ND, Roessler BJ (2001) Topical transfection using plasmid DNA in a water-in-oil nanoemulsion. Int J Pharm 221: 23-34. (Pubitemid 32524032)
87. Xu Y, Szoka FC, Jr. (1996) Mechanism of DNA release from cationic liposome/ DNA complexes used in cell transfection. Biochemistry (Mosc) 35: 5616-5623. (Pubitemid 26143656)
88. Yamato K, Yamada T, Kizaki M, Ui-Tei K, Natori Y, Fujino M, Nishihara T, Ikeda Y, Nasu Y, Saigo K, Yoshinouchi M (2008) New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer. Cancer Gene Ther 15: 140-153. (Pubitemid 351240669)
89. Yoshizawa T, Hattori Y, Hakoshima M, Koga K, Maitani Y (2008) Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. Eur J Pharm Biopharm 70: 718-725.
90. Zou S, Scarfo K, Nantz MH, Hecker JG (2010) Lipid-mediated delivery of RNA is more efficient than delivery of DNA in non-dividing cells. Int J Pharm 389: 232-243.